Skip to main content

Medicare to Negotiate Prices for 15 More Drugs, Including Ozempic

Medically reviewed by Carmen Pope, BPharm. Last updated on Jan 22, 2025.

By India Edwards HealthDay Reporter

WEDNESDAY, Jan. 22, 2025 -- Medicare will soon negotiate prices for 15 more drugs as part of an effort to reduce costs for seniors and people with disabilities, federal health officials announced in a news release.

The negotiations, made possible by the Inflation Reduction Act, will cover widely used medications for conditions such as type 2 diabetes, cancer, and asthma.

The new prices are expected to take effect in 2027.

Between November 2023 and October 2024, these selected drugs accounted for about $41 billion in total covered prescription drug costs under Medicare Part D, or about 14%, according to the U.S. Department of Health and Human Services (HHS).

“Today’s announcement is pivotal -- the Inflation Reduction Act is lowering prices for people on Medicare. HHS will continue negotiating in the best interest of people with Medicare to have access to innovative, life-saving treatments at lower costs," Xavier Becerra, HHS secretary under the Biden administration, said in the release.

Drugs selected for this second round of negotiations include:

The new talks follow last year’s negotiations for 10 high-cost drugs, which resulted in price cuts of 38% to 79%. Those discounts, effective in 2026, are projected to save Medicare $6 billion annually.

Officials plan to expand negotiations to include 15 more drugs in the next cycle and up to 20 more in following years.

“Improving prescription drug affordability for Medicare enrollees is the core of the Inflation Reduction Act, and the next cycle of negotiations will continue to strengthen Medicare for generations to come," Chiquita Brooks-LaSure, administrator of the Centers for Medicare & Medicaid Services, said in the news release.

Sources

  • Centers for Medicare & Medicaid Services, news release, Jan. 17, 2025

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted January 2025

Read this next

FDA Authorizes First AI Platform for Breast Cancer Prediction

FRIDAY, June 6, 2025 -- The U.S. Food and Drug Administration has granted de novo authorization to CLAIRITY BREAST, a first-in-class, image-based platform that can help predict a...

4 States Ask FDA to Lift Rules on Abortion Pill Mifepristone

FRIDAY, June 6, 2025 — Attorneys general from four states are asking the U.S. Food and Drug Administration (FDA) to lift restrictions on mifepristone, a pill used in...

Long-Lasting HIV Prevention Shot Headed Toward Approval

FRIDAY, June 6, 2025 — A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month. If approved, the shot...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.